# The Immunogenicity and Safety Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB001

> **NCT05928455** · EARLY_PHASE1 · UNKNOWN · sponsor: **Guangzhou Patronus Biotech Co., Ltd.** · enrollment: 120 (actual)

## Conditions studied

- COVID-19
- Vaccine Reaction

## Interventions

- **BIOLOGICAL:** LYB001
- **BIOLOGICAL:** CoronaVac

## Key facts

- **NCT ID:** NCT05928455
- **Lead sponsor:** Guangzhou Patronus Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-14
- **Primary completion:** 2022-10-10
- **Final completion:** 2023-06-30
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2023-07-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05928455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05928455, "The Immunogenicity and Safety Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB001". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05928455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*